Noninvasive Determination of CMV Serostatus From Dried Buccal Swab Samples: Assay Development Validation, and Application to 1.2 Million Samples

Background. Buccal swab sampling constitutes an attractive noninvasive alternative to blood drawings for antibody serostatus assays. Here we describe a method to determine the cytomegalovirus immunoglobulin G (CMV IgG) serostatus from dried buccal swab samples. Methods. Upon solubilization, CMV IgG is determined by an ELISA assay specifically adapted to cope with low IgG concentrations. The derived CMV titer is normalized against the total protein concentration to adjust for incorrectly or less efficiently sampled buccal swabs. Assay parameters were optimized on a set of 713 samples. Results. Validation with 1784 samples revealed distinct results for > 80% of samples with 98.6% specificity and 99.1% sensitivity. Based on the analysis of 1.2 million samples we derived age- and sex-stratified CMV prevalence statistics for Germany, Poland, United Kingdom, and Chile. To confirm accuracy of the assay in routine operation, the CMV status of 6518 donors was reassessed by independent laboratories based on conventional blood samples revealing 96.9% specificity and 97.4% sensitivity. Conclusions. The assay accurately delivers the CMV IgG serostatus from dried buccal swab samples for > 80% of the participants. Thereby it provides a noninvasive alternative to plasma-based CMV monitoring for nondiagnostic purposes such as hematopoietic stem cell transplantation donor screening or population studies.

Automated summary

This study presents a method to determine cytomegalovirus immunoglobulin G (CMV IgG) serostatus from dried buccal swab samples with high specificity (98.6%) and sensitivity (99.1%). Analysis of 1.2 million samples resulted in age- and sex-stratified CMV prevalence statistics for Germany, Poland, United Kingdom, and Chile. Reassessment of CMV status in 6518 donors using conventional blood samples showed high specificity (96.9%) and sensitivity (97.4%).